Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carolyn Word

Allergy & Immunology Charleston, SC Medical Doctor

NPI 1003044645 CMS profile 1217341

171 Ashley Ave, Charleston, SC 29425

Open in the dashboard

General payments

$10,206

412 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carolyn Word of Charleston, SC is reported in the CMS Open Payments database as having received $10,206 across 412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,411 55
2024 General $1,871 82
2023 General $2,598 63
2022 General $1,157 58
2021 General $1,337 58
2020 General $978 52
2019 General $854 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carolyn Word
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Carolyn Word were reported at $1,411. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Carolyn Word Allergy & Immunology median Middle half National median
2019 $854 $594 $163–$1,512 $163
2020 $978 $426 $106–$1,233 $114
2021 $1,337 $638 $157–$1,708 $132
2022 $1,157 $790 $205–$1,961 $149
2023 $2,598 $852 $220–$2,147 $160
2024 $1,871 $865 $203–$2,267 $164
2025 $1,411 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $2,409 45 payments
  2. AstraZeneca Pharmaceuticals LP $2,100 102 payments
  3. GlaxoSmithKline, LLC. $794 44 payments
  4. CSL Behring $574 25 payments
  5. Genentech USA, Inc. $555 22 payments
  6. Pfizer Inc. $554 25 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $380 16 payments
  8. Regeneron Healthcare Solutions, Inc. $356 15 payments
  9. BioCryst US Sales Co., LLC $298 10 payments
  10. Amgen Inc. $267 12 payments
  11. Other $1,919 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,794 405 payments
  2. Consulting Fee $1,183 2 payments
  3. Education $229 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $3,254 75 payments
  2. FASENRA $975 45 payments
  3. TEZSPIRE $621 27 payments
  4. Xolair $528 21 payments
  5. AIRSUPRA $369 17 payments
  6. NUCALA Immunology $355 18 payments
  7. DUPIXENT Inflammation And Immunology $322 14 payments
  8. Hizentra $299 11 payments
  9. Orladeyo $298 10 payments
  10. NUCALA Respiratory $292 18 payments
  11. Other $4,347 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

486

Median for Allergy/ Immunology: 449

Drug cost

$67,573

Median for Allergy/ Immunology: $169,700

Branded share of claims

34.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breo Ellipta Fluticasone/Vilanterol Brand 41 $24,834
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $17,946
Cromolyn Sodium Generic 12 $4,241
Omnaris Ciclesonide Brand 11 $3,039
Pulmicort Flexhaler Budesonide Brand 12 $2,982
Azelastine-Fluticasone Azelastine/Fluticasone Brand 20 $2,732
Wixela Inhub Fluticasone Propion/Salmeterol Brand 15 $2,348
Bepotastine Besilate Generic 13 $2,037
Epinephrine Generic 12 $1,735
Azelastine Hcl Generic 28 $1,195

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$112,751

Of which drugs: $85,083

Medicare patients

305

Average age 72

Services billed

4,590

217 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 56%
Diabetes 27%
Ischemic heart disease 22%
Depression 19%
Osteoporosis 19%
Chronic kidney disease 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 12 1,486 $44,768

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $336
  • Regeneron Healthcare Solutions, Inc. $64
$400 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $195
  • Amgen Inc. $31
$226 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $203
$203 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $188
$188 — —
XOLAIR
  • Genentech USA, Inc. $126
  • Novartis Pharmaceuticals Corporation $27
$153 — 1,486

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record